Dolutegravir + Lamivudine vs. Dolutegravir + Tenofovir Disoproxil Fumarate/Emtricitabine: Very-Low-Level HIV-1 Replication through 144 Weeks in the GEMINI-1 and GEMINI-2 Studies

In GEMINI-1/-2, dolutegravir + lamivudine was non-inferior to dolutegravir + tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) in achieving viral suppression (viral load [VL] < 50 copies/mL) in treatment-naive adults. Abbott’s RealTime HIV-1 assay provides quantitative VL (40–10,000,000 copies/m...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Mark Underwood, Rimgaile Urbaityte, Ruolan Wang, Joe Horton, James Oyee, Brian Wynne, Dainielle Fox, Bryn Jones, Choy Man, Jörg Sievers
Format:	Artigo
Sprog:	Inglês
Udgivet:	MDPI AG 2024-03-01
Serier:	Viruses
Fag:	antiretroviral therapy two-drug regimen DTG + 3TC HIV-1 infection very-low-level viremia virologic response
Online adgang:	https://www.mdpi.com/1999-4915/16/3/405
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!